« Previous
Next »
Surgery
Volume 148, Issue 3
, Pages
567-572
, September 2010
The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine
To access this article, please choose from the options below
Conflict of interest: The authors are currently engaged in an unrelated, sponsored clinical trial using taurolidine.
PII: S0039-6060(10)00022-X
doi: 10.1016/j.surg.2010.01.006
© 2010 Mosby, Inc. All rights reserved.
« Previous
Next »
Surgery
Volume 148, Issue 3
, Pages
567-572
, September 2010
